Diabetes
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy
Medical Information | Non-US Health Care Professionals
Account Settings
Sign Out
Sign In | Create Account
Diabetes
Time in Range (TIR)
Time in Range (TIR)
  • Overview
    • What is Time in Range (TIR)?
    • Why TIR matters
    • Clinical guidance and targets
    • How to use TIR in clinical practice
    • Understanding the AGP
    • Getting started with TIR
    • Using TIR to create action
  • Continuous glucose monitoring
  • Expert insights
  • Patient stories
calendar icon

USING TIME IN RANGE (TIR) TO CREATE AN ACTION PLAN FOR EFFECTIVE GLYCEMIC CONTROL

When discussing Time in Range (TIR) with people with diabetes, it is important to understand their daily habits. Healthcare professionals should examine the ambulatory glucose profile (AGP) report (see example below), which includes metrics such as TIR, Time Above Range (TAR), and Time Below Range (TBR). It also displays mean glucose levels and glycemic variability throughout each day and night over a certain time period (normally 14 days).1,2

Example one-page AGP Report
Example one-page AGP Report mobile version

TIR HCP Educational Content: Time in Range KOL Video of Dr. Cheng
(10:46)

Dr Alice Cheng, University of Toronto, shares her recommendations for discussing CGM data with patients. 

Healthcare professional has received a fee from Novo Nordisk Inc. for her participation.

During appointments, consider taking the following steps1‑4:

  • Review hemoglobin A1c (HbA1c) levels
  • Analyze the 14-day data from the AGP report, with a particular focus on TIR, TBR, TAR, and glycemic variability
  • In the AGP stacked bar chart: 
    • TIR is reflected in green and should be at least 70% of the day
    • TBR, reflected in red (low) and dark red (very low), should be less than 4% of the day. Less than 1% of the day should be spent in the dark red “very low” range
    • TAR, reflected in yellow (high) and orange (very high), should be less than 25% of the day. Less than 5% of the day should be spent in the orange “very high” range
  • If the stacked bar chart in the AGP report has a higher proportion of readings on either side of the green section, have a conversation with the person about why hypoglycemia or hyperglycemia may be occurring
  • Review the AGP report to identify the timings and magnitudes of the problem areas. The first priority is to address hypoglycemia
    • It may be necessary to review multiple daily glucose profiles to identify any particular weekdays or weekends when the patterns are most notable
  • Have a conversation with the person about how they might prevent these fluctuations in glucose levels in the future
  • Review the treatment regimen and agree on an action plan

Learn more about TIR and other CGM metrics

To help people with diabetes understand how TIR relates to their diabetes management, it is useful to frame TIR targets as hours and minutes, rather than percentages.1 For example, instead of advising people to spend no more than 4% of the day below range, explain how they should aim to spend less than 1 hour per day below range. This eliminates any guesswork and provides clear and actionable targets.

Healthcare professionals should also review other variables that may affect a person’s glucose profile when making decisions about potential therapeutic interventions. These may include factors such as age, weight, and body mass index; diabetes treatment, insulin dosage, and timing of doses; and sleep, diet, and exercise habits.1,2


  1. Battelino T, Danne T, Bergenstal RM, et al. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019;42(8):1593-1603.
  2. American Diabetes Association. Standards of Care in Diabetes—2023. Diabetes Care. 2023;46(suppl 1):S1-S291.
  3. Wright EE Jr, Morgan K, Fu DK, Wilkins N, et al. Time in Range: How to Measure It, How to Report It, and Its Practical Application in Clinical Decision-Making. Clin Diabetes. 2020;38(5):439-448.
  4. Wysham CH, Kruger DF. Practical Consideration for Initiating and Utilizing Flash Continuous Glucose Monitoring in clinical Practice. Journal or Endocrine Society. 2021. Epub ahead of print. doi:10.1210/jendso/bvab064.

CLINICAL USE

healthcare professional icon in blue

How to use TIR in clinical practice

AGP logo in blue

Understanding the AGP

stethoscope icon in blue

Getting started with TIR

calendar icon in blue

Using TIR to create action

Diabetes
Explore diabetes
Explore obesity
Explore growth-related disorders
Explore rare bleeding disorders
Explore rare renal disorders
Explore hormone replacement therapy

novoMEDLINK™ is a trademark of Novo Nordisk A/S.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.

Terms of Use | Privacy Notice | Consumer Health Privacy Notice | Cookie Notice | Privacy Request | Contact Us |
novonordisk-us.com    
© 2023 Novo Nordisk All rights reserved. US21HCP00098 November 2023

Quick links

Request medication samples

Diabetes treatment guidelines

Patient savings card offer

Patient support program